Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BDSX
BDSX logo

BDSX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Biodesix Inc (BDSX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
16.810
1 Day change
10.45%
52 Week Range
20.210
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Biodesix Inc (BDSX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 to invest. The stock has strong bullish momentum, positive analyst sentiment, and hedge fund buying activity, which align with long-term growth potential.

Technical Analysis

The technical indicators for BDSX are bullish. The MACD is positively expanding, the RSI is in a neutral zone at 72.335, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock has broken through key resistance levels, with the next resistance at R2: 17.514.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
13

Positive Catalysts

  • Analysts have raised price targets recently, with Canaccord increasing the target to $27 and H.C. Wainwright initiating coverage with a $26 target. Both firms maintain a Buy rating.

  • Hedge funds are significantly increasing their buying activity, up 1991.20% over the last quarter.

  • The stock has a 27.17% chance of increasing in the next month based on historical patterns.

Neutral/Negative Catalysts

  • Insiders are selling, with a 531.80% increase in selling activity over the last month.

  • No recent news or updates on the company's operations or financials.

Financial Performance

Financial data for the latest quarter is unavailable, but analysts highlight operating leverage and a path towards sustainable profitability. The company is nearing adjusted EBITDA breakeven.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is highly positive. Recent price target increases and Buy ratings from Canaccord and H.C. Wainwright reflect confidence in the company's growth trajectory and operational improvements.

Wall Street analysts forecast BDSX stock price to rise
4 Analyst Rating
Wall Street analysts forecast BDSX stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 15.220
sliders
Low
20
Averages
30
High
40
Current: 15.220
sliders
Low
20
Averages
30
High
40
Canaccord
Buy
maintain
$22 -> $27
AI Analysis
2026-06-18
New
Reason
Canaccord
Price Target
$22 -> $27
AI Analysis
2026-06-18
New
maintain
Buy
Reason
Canaccord raised the firm's price target on Biodesix to $27 from $22 and keeps a Buy rating on the shares. The firm updated its model following investor/management meetings. Investors were more interested in its hiring strategy while management focused on capital conservation as the company approaches adjusted EBITDA breakeven. They alos noted the company could provide a test pipeline update at the Association for Molecular Pathology (AMP) 2026 Meeting in November.
H.C. Wainwright
H.C. Wainwright
initiated
$26
2026-06-15
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$26
2026-06-15
New
initiated
Reason
H.C. Wainwright initiated coverage of Biodesix with a Buy rating and $26 price target. Biodesix is a commercial-stage diagnostics company concentrated on lung disease, combining genomics, proteomics, and radiomics, the analyst tells investors in a research note. The firm says Biodesix is showing operating leverage and is on a path towards achieving sustainable profitability in the coming years.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BDSX
Unlock Now

People Also Watch